During the course of your cancer diagnosis and treatment, your physician may order next-generation DNA sequencing. No two cancers are the same. Next-generation DNA sequencing is a test your physician may use to better understand the unique molecular composition of your cancer.
Overview
A next-generation DNA sequencing lab report can help your physician at different stages of your cancer journey:
- Diagnosing the tumor’s specific genetic mutations
- Predicting how your cancer may react to certain treatments
- Identifying specific drugs that will most effectively treat the specific composition of your tumor
- Changing your care plan if you are no longer responding to your treatment
- Matching you to clinical trials that may be a fit for you
Our approach
Our Laboratory Medicine and Pathology department, in partnership with Fairview Laboratories, brings leading-edge technology to patient care. This translates to personalized care in which scientists, physicians, and patients work together to choose the best treatment plan for each unique patient.
Prosigna Breast Cancer Gene Signature Assay
If you have been diagnosed with breast cancer, your physician may suggest the Prosigna Breast Cancer Gene Signature Assay test. This test looks at 50 genes in your breast cancer cells that reveal unique traits of your cancer. It is designed to predict the likelihood that your breast cancer will return, to any part of your body, over the next 10 years.
The Prosigna Breast Cancer Gene Signature Assay is a genomic test used for women who are newly diagnosed, early stage (I or II), with invasive breast cancer. The cancer must be hormone receptor positive and either lymph-node negative or lymph-node positive with 3 or fewer positive nodes.
Your Prosigna genomic test will return a score between 0-100, indicating your likelihood of cancer recurrence. The lower the score, the less likely it is your cancer will return. The higher the score, the more likely it will return over the next 10 years.